PSA Test (Prostate-Specific Antigen)

Total PSA is the basic measurement used in initial risk assessment. It is a starting point, not a stand-alone indication for biopsy.

The total PSA value should always be considered together with age, history, DRE and prostate volume before it leads to any decision about further testing.

PSA density = PSA ÷ prostate volume. Prostate volume can be estimated with transrectal ultrasound (TRUS) or MRI.

A larger prostate produces more PSA even from benign tissue alone. PSA density puts a value into context relative to gland size.

Illustrative example: a PSA of 5 ng/mL in a 30 mL prostate does not carry the same clinical meaning as a PSA of 5 ng/mL in a 100 mL prostate. This is an illustrative example, not a diagnosis.

According to current EAU guidance, higher PSA density is associated with a greater likelihood of clinically significant cancer, particularly in smaller glands, and is one of the strongest independent factors in modern risk calculators. It should always be interpreted together with mpMRI, family history and the overall clinical picture — never as an isolated binary cut-off.

PSA can be elevated by multiple causes, both benign and malignant. Recognizing these factors is central to correctly interpreting any value.

Inflammation or infection of the prostate can significantly raise PSA — sometimes to very high levels, with full normalization taking up to several months.

A PSA test taken during an active febrile UTI or significant acute prostatitis can be misleading.

PSA is not used to diagnose prostatitis. See acute prostatitis and chronic prostatitis.

When repeating PSA for a borderline or uncertain value, standardized measurement conditions are used according to current guidance: the same laboratory/assay where feasible, no active urinary infection, and no recent significant prostate manipulation.

• A recent prostate biopsy can significantly affect PSA — the test should not be interpreted immediately after biopsy, and a delay of at least one month before re-testing is recommended.
• Recent ejaculation is sometimes cited as a possible cause of transient variation, though the evidence is less robust than for infection, retention or biopsy — a rigid, universal abstinence interval should not be applied without individualization.
• Cycling is occasionally mentioned as a possible factor, but the evidence is less consistent than for infection or retention — it is not a universal, established cause of PSA elevation.

Medications such as finasteride and dutasteride, used for benign prostatic hyperplasia, lower measured PSA by roughly 50% after prolonged use.

A PSA value in a man on a 5-alpha-reductase inhibitor should not be interpreted the same way as in a man not taking this treatment. The urologist should account for this correction before deciding on further work-up.

PSA density is less affected, because prostate volume decreases in parallel with PSA.

Do not stop this medication on your own — interpretation is done by your urologist, taking the treatment into account.

Procedures that remove or reduce prostate tissue — such as HoLEP, TURiS, Aquablation or Rezūm — can change your future PSA baseline.

The meaning of a post-operative value depends on the type of procedure, the amount of tissue remaining, the pathology result, and the time elapsed. There is no single, universal expected percentage decrease in PSA across all techniques and all patients.

PSA behavior after radiotherapy differs significantly from that after radical prostatectomy, because the prostate remains in place and continues to produce PSA. The same interpretation logic used after prostatectomy should not be applied. Biochemical recurrence criteria after radiotherapy are a specialized follow-up topic for known disease and are covered on the prostate cancer page.

According to current EAU 2026 guidance, in asymptomatic men with a PSA of 3–10 ng/mL and no suspicious findings on palpation, it is initially recommended to repeat PSA testing before further investigation.

In practice, a second measurement after about four weeks helps confirm whether the initial value was truly elevated: in a substantial proportion of men, the repeat value normalizes. If PSA normalizes, a new test can be scheduled after about one year, depending on the overall risk profile.

Repeat testing should be done at the same laboratory, using the same assay where feasible, under standardized conditions — without active urinary infection or recent significant manipulation.

According to current EAU 2026 guidance, early PSA testing in informed men with a life expectancy of at least 15 years can be offered as follows:

• From age 50 in average-risk men.
• From age 45 in men with a family history of prostate cancer or of African descent.
• From age 40 in BRCA2 mutation carriers.

Age is not the only decision factor; life expectancy, comorbidities and patient preference after informed discussion (shared decision-making) are always considered.

For men who remain under surveillance after an initially low value, follow-up frequency can be individualized: more frequent checks (e.g., every two years) in men with a relatively higher initial PSA, and less frequent checks in those with a lower initial PSA, always in agreement with their urologist.

European (EAU) and American (AUA/SUO) guidelines do not use identical wording regarding the starting ages for testing. They should not be artificially merged into a single, universal rule.

• EAU guidance proposes specific starting ages based on risk (see above) and a life expectancy of at least 15 years.
• AUA/SUO guidance emphasizes a framework of individualized, informed shared decision-making based on age, risk, and the use of validated risk calculators.

A shared principle of both: early detection should be individualized, based on informed shared decision-making rather than a rigid age rule.

BRCA2 mutation carriers have an increased risk of prostate cancer and often develop it at a younger age, which is why early PSA testing can start from age 40. BRCA1 mutations or other hereditary cancer syndromes may carry similar relevance, according to individualized clinical assessment.

Germline genetic testing is discussed in selected families with multiple early-onset cancers and is always accompanied by genetic counseling. We do not promote commercial self-testing genetic kits.

A suspicious digital rectal examination raises clinical concern even when PSA is not markedly elevated. Combining PSA and DRE improves risk assessment compared with either alone. A normal DRE does not exclude prostate cancer.

PSA and mpMRI answer different questions: PSA is a biological risk marker, while MRI is an anatomical/imaging risk-stratification tool. MRI is not used as an initial mass-screening tool according to current guidance — it comes after the initial PSA/DRE assessment, not instead of it.

Biopsy is not an automatic consequence of every elevated PSA. The decision weighs: repeat PSA, DRE, PSA density, mpMRI findings, family history and, in selected cases, risk calculators or additional biomarkers.

No single PSA value should be interpreted as an automatic indication for biopsy, except in rare cases of a very strong clinical picture where current guidance supports immediate work-up. See transrectal prostate biopsy and MRI fusion biopsy.

For a reliable measurement, tell your urologist about:

• Any active or recent urinary tract infection.
• A recent episode of urinary retention.
• A recent prostate biopsy or other manipulation (e.g., catheterization, cystoscopy).
• Recent ejaculation, if asked.
• Medications such as finasteride/dutasteride or testosterone therapy.
• Any prior prostate surgery.

Do not stop prescribed medication on your own, do not start antibiotics "to lower your PSA," and do not self-treat suspected prostatitis without medical guidance.

The goal is not to artificially lower the laboratory number, but to understand why it is elevated.

Not recommended: dietary supplements promising to lower PSA, antibiotics without an indication, extreme diets, or stopping medication on your own. The right approach is a structured diagnostic assessment, not "correcting" the number.

Symptoms such as frequency, nocturia, weak stream, or urgency are often related to BPH or another benign lower-urinary-tract condition, not necessarily cancer.

Conversely, early prostate cancer is often asymptomatic. Therefore, neither the presence nor the absence of symptoms alone is sufficient to guide the decision about PSA testing.